(Total Views: 528)
Posted On: 04/23/2017 8:48:16 PM
Post# of 30066
Novartis should just give up because there is at least one or two other companies much further along. Here's one: https://www.adamaspharma.com/pipeline/
Why in the world would a large company like Novartis continue such a futile effort throwing good money after bad.
Unless like Elto, there are a number of other indications or they believe Mavoglurant is better than ADS-5102
The other thing about treatment of Levodopa-induced Dyskinesia (LID) is there may likely not be a perfect solution. If there is, that would be great for all that suffer. But if a better solution comes along, they will likely take the lion's share, even if the tortoises, Novartis and Amarantus don't place first.
Adamas will announce phase III data in another week, but the stock has been heading down. Either a buying op or the data isn't too hot. Pipeline already shows then moving past phase III?
Why in the world would a large company like Novartis continue such a futile effort throwing good money after bad.
Unless like Elto, there are a number of other indications or they believe Mavoglurant is better than ADS-5102
The other thing about treatment of Levodopa-induced Dyskinesia (LID) is there may likely not be a perfect solution. If there is, that would be great for all that suffer. But if a better solution comes along, they will likely take the lion's share, even if the tortoises, Novartis and Amarantus don't place first.
Adamas will announce phase III data in another week, but the stock has been heading down. Either a buying op or the data isn't too hot. Pipeline already shows then moving past phase III?
(2)
(0)
